Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction.

European Heart Journal Cardiovascular Imaging
Biniyam G DemisseiBonnie Ky

Abstract

We aimed to determine the early changes and predictive value of left ventricular (LV) segmental strain measures in women with breast cancer receiving doxorubicin. In a cohort of 237 women with breast cancer receiving doxorubicin with or without trastuzumab, 1151 echocardiograms were prospectively acquired over a median (Q1-Q3) of 7 (2-24) months. LV ejection fraction (LVEF) and 36 segmental strain measures were core lab quantified. A supervised machine learning (ML) model was then developed using random forest regression to identify segmental strain measures predictive of nadir LVEF post-doxorubicin completion. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as a ≥10% absolute LVEF decline pre-treatment to a value <50%. Median (Q1-Q3) baseline age was 48 (41-57) years. Thirty-five women developed CTRCD, and eight of these developed symptomatic heart failure. From pre-treatment to doxorubicin completion, longitudinal strain worsened across the basal and mid-LV segments but not in the apical segments; circumferential strain worsened primarily in the septum; radial strain worsened uniformly and transverse strain remained unchanged across all LV segments. In the ML model, anterolateral and inferoseptal circumferentia...Continue Reading

References

Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Narumol ChaosuwannakitW Gregory Hundley
Nov 20, 2010·Journal of the American College of Cardiology·Chung-Lieh HungUNKNOWN VALIANT investigators
Oct 4, 2011·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Paul W StoodleyLiza Thomas
May 15, 2012·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Joseph T PoteruchaBenjamin W Eidem
Sep 6, 2012·Journal of the National Cancer Institute·Erin J Aiello BowlesUNKNOWN Pharmacovigilance Study Team
Apr 9, 2013·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Kazuaki NegishiThomas H Marwick
Aug 14, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Paul W StoodleyLiza Thomas
Mar 4, 2014·Journal of the American Heart Association·Ghideon EzazJersey Chen
Aug 31, 2014·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Juan Carlos PlanaPatrizio Lancellotti
Sep 29, 2017·Circulation. Cardiovascular Imaging·Mir HenglinSusan Cheng
Oct 23, 2017·JACC. Cardiovascular Imaging·Julian BetancurPiotr J Slomka
Mar 23, 2019·Journal of the American College of Cardiology·Damini DeyThomas H Marwick

❮ Previous
Next ❯

Citations

Mar 16, 2021·European Heart Journal Cardiovascular Imaging·Gerald Maurer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.